Sep 18 |
Nanobiotix reports 1H results
|
Sep 18 |
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
|
Sep 4 |
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
|
Sep 3 |
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
Jun 12 |
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
|
Jun 11 |
Voting Rights and Shares Capital of the Company
|
Jun 2 |
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
|
May 28 |
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
|
May 23 |
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
|
May 23 |
Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript
|